RESULTS OF MEDICAL PLASMAPHERESIS APPLICATION IN THE TIME OF DISLEPIDEMICS
https://doi.org/10.51523/2708-6011.2008-5-3-10
Abstract
Представлен анализ ближайших результатов проведения лечебного плазмафереза как метода экстракорпоральной терапии у пациентов с дислипидемиями, прогностически неблагоприятными по развитию атеросклероза. Показана высокая эффективность, безопасность и удовлетворительная переносимость данного метода терапии.
About the Authors
A. V. Korotaev
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
V. Yu. Pogorelov
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
T. V. Kozlovskaya
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
E. V. Tsitko
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
M. G. Rusalenko
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
References
1. Превентивная кардиология / А. В. Виноградов [и др.]. - М., 1987. - С. 430-447.
2. Simons, L. A. Interrelation of lipids and lipoproteins with coronary artery disease mortality in 19 countries / L. A. Simons // Am. J. Cardiol. - 1986. - № 57. - P. 5-10.
3. Seman, L.J. Lipoprotein(a), homocysleine, and remnant-like particles: emerging risk factors / L. J. Seman, L. R. McNamara, E. J. Schaefer // Curr. Opin. Cardiol. - 1999. - Vol. 14. - P. 186-191.
4. Havel, R. J. Remnant lipoproteins as therapeutic targets / R. J. Havel // Curr Opin Lipidol. - 2000. - Vol. 11. - P. 615-620.
5. Remant-likeparticle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study / J. R. McNamara [et al.] // Atheroscklerosis. - 2001. - Vol. 154. - P. 229-236.
6. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease / K. Kugiyama [et al.] // Circulation. - 1999. - Vol. 95. - P. 2858-2860.
7. Gastelli, W. P. Epidemiology of triglycerides: a view from Framingham. / W. P. Gastelli // Am. J. Cardiol. - 1992. - № 70. - P. 3-9.
8. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts) // Eur. Heart. J. - 2003. - № 24. - P. 1601-1610.
9. Российские рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза», Комитет экспертов ВНОК // Кардиоваскулярная терапия и профилактика. - 2004. - № 2 (приложение). - 35 с.
10. Томсон, Г. Р. Руководство по гиперлипидемии / Г. Р. Томсон // MSO Merck Sharp & Dohme Chibret., 1991. - 255 c.
11. Familial Hypercholesterolaemia Regression Study: a randomized trial of low density-lipoprotein apheresis / G. R. Thompson [et al.] // Lancet. - 1995. - № 345. - P. 811-816.
12. Thompson, G. R. Progression and regression of coronary artery disease / G. R. Thompson // Curr. Opin. Lipidol. - 1992. - № 3. - P. 263-267.
13. LDL-apheresis and regression of atherosclerosis / V. V. Tertov [et al.] // Lancet. - 1985. - № 1 (8437). - P. 1108-1109.
14. Tasaki, H. Low-density lipoprotein apheresis in the prevention of recurrent coronary heart disease / H. Tasaki // Therap. Apher. and Dial. - 2003. - № 7 (4). - P. 408-412.
15. Thompson, G. R. LDL apheresis / Atherosclerosis. - 2003. - № 167. - P. 1-13.
Review
For citations:
Korotaev A.V., Pogorelov V.Yu., Kozlovskaya T.V., Tsitko E.V., Rusalenko M.G. RESULTS OF MEDICAL PLASMAPHERESIS APPLICATION IN THE TIME OF DISLEPIDEMICS. Health and Ecology Issues. 2008;(3):52-56. (In Russ.) https://doi.org/10.51523/2708-6011.2008-5-3-10
Views: 239
Email this article 